ProtoKinetix Highlights AAGP(TM) Development and Production Strategy.VANCOUVER, British Columbia -- ProtoKinetix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : PKTX) summarizes the highlights of the scientific accomplishments attained over the last 24 months to develop a commercially viable group of products. The first hurdle was to determine that the AAGP AAGP American Association of Grant Professionals AAGP American Association of Geriatric Psychiatry AAGP American Academy of General Practice AAGP Aerobic Attached Growth Process AAGP Aeromedical Airlift Group AAGP Acoustic Analysis Guidance Product (TM) molecule was stable and lacked toxicity. Upon these confirmations, PKTX concentrated on human cell preservation at various temperatures. Early studies showed a greater than 300% increase in cell preservation down to -20 (o)C. Efficacy test results showed a 98% red blood cell red blood cell: see blood. preservation after being subjected to -15 (o)C for 9 hrs as opposed to 100% mortality for cells not treated. Further tests showed a significant reduction of platelet aggregation Platelet aggregation The clumping together of blood cells, possibly forming a clot. Mentioned in: Herbalism, Traditional Chinese from 22 (o)C to 0 (o)C. Scientists at the University of Rouen expanded the family of AAGP(TM)molecules and found them to be stable and safe. A third party laboratory found that AAGP(TM) increased heart cell and heart tissue survivability sur·viv·a·ble adj. 1. Capable of surviving: survivable organisms in a hostile environment. 2. That can be survived: a survivable, but very serious, illness. . AAGP[TM] was shown to slow the aging process of human skin cells at temperatures ranging from 37oC (core body temperature) down to (o)C. More intense stress to human skin cells using H2O2 and UV-C UV-C Far-UltraViolet resulted in successful preservation when treated with AAGP(TM).World wide patents and subsequent extensions were then filed. After laying the above scientific foundations, in 2006 ProtoKinetix began to concentrate on trials that were targeted toward specific markets. At the request of a cosmetic corporation, the Company conducted trials using very low concentrations of AAGP(TM). The results showed minimal decline in the preservative effects attained. Again, targeting the cosmetic market, PKTX showed that AAGP(TM) proves to be a powerful additive compared to coenzyme Q coenzyme Q n. Ubiquinone. 10 and side by side. Third party testing showed that lengthy exposure to AAGP(TM) maintained cell integrity and function even with high concentrations of the molecule (15 mg/ml). Patent expansions included AAGP(TM) molecules ranging from the very smallest (320 daltons) single amino acid amino acid (əmē`nō), any one of a class of simple organic compounds containing carbon, hydrogen, oxygen, nitrogen, and in certain cases sulfur. These compounds are the building blocks of proteins. based molecule through to the largest (2.2 kilodaltons) AAGP(TM) molecule that would have any practical application. INSA INSA Institut National des Sciences Appliquées (French) INSA Indian National Science Academy INSA Indian National Shipowners' Association INSA Instituto Nacional de Saúde Ricardo Jorge (Portugal) (Frances National Institute of Applied Science) chose AAGP(TM) as its project to present at the annual GECO GECO Groupe d'Étude en Chirurgie Osseuse GECO Gustave Genschow Co. (German cartridge headstamp) Conference. ProtoKinetix' lead scientist was awarded the prestigious Francinov Award for the development of the AAGP(TM) family of molecules. Recent studies have shown that AAGP(TM) significantly reduces inflammation. This new development has opened up several avenues for research and business development. The latest UV exposure experiments suggest that AAGP(TM) not only protects cells from UV light but may also be acting at a molecular level to induce the repair of damaged cells. A new market for AAGP(TM) has been opened up by the discovery that the addition of this molecule to a solution of DMSO DMSO dimethyl sulfoxide. DMSO n. Dimethyl sulfoxide; a colorless hygroscopic liquid obtained from lignin, used as a penetrant to convey medications into the tissues. DMSO, n. in cryopreservation cryopreservation /cryo·pres·er·va·tion/ (-prez?er-va´shun) maintenance of the viability of excised tissue or organs by storing at very low temperatures. cry·o·pres·er·va·tion n. of cell lines increased the thawed out cell viability by 100%. Capitalizing on the significant scientific breakthroughs accomplished over the last few months, ProtoKinetix has a wide range of choices for maximizing the commercial value of the Company. PKTX' focus for 2007 is to launch AAGP(TM) into the markets which require no regulatory approval to a fast track approval. These markets include: 1. Skin care applications - anti-aging and anti-oxidant additives for cosmetic use 2. Sun protection agents - protection and repair 3. Cryopreservation of cells and tissues 4. Preservation of organs, islets and skin cells for transplantation In anticipation of successful contractual negotiations in the first quarter of this year, ProtoKinetix has entered into discussion with major chemical corporations to dramatically ramp up Ramp Up To increase a company's operations in anticipation of increased demand. Notes: A company might 'ramp up' operations if they just signed a contract creating substantially more demand for their product. See also: Demand, Economies of Scale the production of the AAGP(TM) family of molecules. As of this date, PKTX has entered into 6 specific application development agreements with major universities, institutions and corporations. These developments will very quickly establish the market value of AAGP(TM) which will ultimately determine the long term value of the Company. About ProtoKinetix: ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze antifreeze, substance added to a solvent to lower its freezing point. The solution formed is called an antifreeze mixture. Antifreeze is typically added to water in the cooling system of an internal-combustion engine so that it may be cooled below the freezing point glycoproteins (AAGP[TM]) for human and veterinary medicine veterinary medicine, diagnosis and treatment of diseases of animals. An early interest in animal diseases is found in ancient Greek writings on medicine. Veterinary medicine began to achieve the stature of a science with the organization of the first school in the , the biotechnology and cosmetic industries, and as a food additive. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to PKTX's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for PKTX's products. PKTX undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in PKTX's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact PKTX's success are more fully disclosed in PKTX's most recent public filings with the U.S. Securities and Exchange Commission. On behalf of the Board of Directors Dr. John Todd - President Company Office: Suite # 1500 885 West Georgia Street Vancouver, BC V6C 3E8 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion